linsitinib Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Linsitinib is an experimental drug candidate for the treatment of various types of cancer. It is an inhibitor of the insulin receptor and of the insulin-like growth factor 1 receptor (IGF-1R). This prevents tumor cell proliferation and induces tumor cell apoptosis.   Wikipedia

Chemistry

  • SMILES: C[C@@]1(O)C[C@@H](C1)c2nc(c3ccc4ccc(nc4c3)c5ccccc5)c6c(N)nccn26
  • InChIKey: PKCDDUHJAFVJJB-VLZXCDOPSA-N
  • Mol. Mass: 421.5
  • ALogP: 4.82
  • ChEMBL Molecule:
    linsitinib  
More Chemistry

Pharmacology

Alternative names

3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol | asp7487 | asp-7487 | linsitinib | osi906 | osi 906 | osi-906 | osi-906aa

Organizations (22)

Research & Development (22)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (29)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (29)


 

Adrenocortical Carcinoma (Phase 3)

Breast Neoplasms (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Squamous Cell (Phase 1/Phase 2)

Carney Complex (Phase 2)

Chondrosarcoma (Phase 2)

Colorectal Neoplasms (Phase 1)

Endocrine System Diseases (Phase 2/Phase 3)

Exophthalmos (Phase 2/Phase 3)

Eye Diseases (Phase 2/Phase 3)

Gastrointestinal Stromal Tumors (Phase 2)

Graves Ophthalmopathy (Phase 2/Phase 3)

Hashimoto Disease (Phase 2/Phase 3)

Head and Neck Neoplasms (Phase 2)

Insulin-Like Growth Factor I (Phase 2/Phase 3)

Liver Neoplasms (Phase 2)

Multiple Myeloma (Phase 1/Phase 2)

Neoplasms (Phase 2)

Orbital Diseases (Phase 2/Phase 3)

Ovarian Neoplasms (Phase 1/Phase 2)

Pancreatic Neoplasms (Phase 1/Phase 2)

Paraganglioma (Phase 2)

Pharmacokinetics (Phase 1)

Prostatic Neoplasms (Phase 2)

Sarcoma, Ewing (Phase 2)

Skin Neoplasms (Phase 1/Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Thyroid Diseases (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 26
  • # of Trial Organizations: 22

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue